Current Deal Pipeline
We have strong pipeline of pharmaceutical deals spread over different business models such as finished dosage formulations, API and CDMO with a potential aggregate value of near US$ 1 Billion
USD 250 Mn Majority stake sale in a branded domestic formulations player based in India that focuses on super specialty chronic segments
Secondary deal providing an exit to existing investors and additional liquidity to Promoter/Management team.
USD 200 Mn Majority investment in a US-based vertically integrated specialty pharmaceutical company focused on development, manufacturing and marketing of finished dosage formulations and APIs & intermediates in regulatory and emerging markets
The company plans to utilize the funds for expanding their R&D and manufacturing infrastructure.
USD 150 Mn majority investment into US based Specialty CDMO focused on development and manufacturing of Phase1/ Phase 2 / Phase 3 & Commercial APIs products for large and biotech companies
The company plans to utilize the funds for expanding their R&D and manufacturing infrastructure and forward integrate into finished dosage formulations.
USD 200 Mn Majority stake in one of the leading full service small molecule API CDMO player headquartered in Europe
The company plans to utilize the funds for making acquisitions to vertically integrate their business and also spend capex on increasing existing capacities.
US$ 50 Mn+ PE/buy-out credentials
Sub US$ 50 Mn PE credentials
